BRVEBraveheart Bio, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Enriched 2026-08-14 20:47

Market cap: —
Shares outstanding (class): —
Shares outstanding (weighted): —
SIC: —
Employees: —
Location: —
Homepage: https://www.braveheart.bio
Description: Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

Market cap and share counts drift.

as of 2026-03-31

No reported positions at this date.

Positions are reached through OpenFIGI-resolved ISINs. A security with no resolved ISIN cannot be found this way even if funds do hold it.

master.security_identifier

Not classified.

5,771 of 13,106 active securities have an assignment so far. This one is still in the queue.

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.